COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Merck has joined the fight against COVID-19 by acquiring OncoIummune in an all-cash transaction.
Shares of COVID-19 vaccine duo Pfizer and BioNTech made handy gains on Wednesday after they announced their late-stage coronavirus study had concluded.
Moderna reported a 95.4% effectiveness rate for its COVID-19 vaccine. This is the second vaccine to hit more than 90% efficacy in the past week.
Pfizer and BioNTech stocks both exploded on Monday after these companies provided an update on their coronavirus vaccine.
Regeneron Pharma reported its third-quarter financial results before the markets opened on Thursday.
Merck and Pfizer reported their most recent quarterly results before the opening bell Tuesday, and investors were not thrilled about this quarter for these two pharmaceutical giants.
Clinical-stage biopharmaceutical company Atea Pharma intends to price 11 million shares for and intial public offering valued up to more than $303 million.
Are BioSpecific Technologies shareholders actually getting a good deal from the merger agreement with Endo International?
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic...
While other companies seem to be struggling with their coronavirus vaccines, Pfizer and BioNTech are just picking up speed. Pfizer’s CEO has provided an update on their COVID-19 vaccine.
Earnings season has kicked off and investors are already chasing the winners higher and punishing the losers. It is not exactly a secret that investors chase performance. That’s why it is so...
Johnson & Johnson released better than expected quarterly results before the markets opened on Tuesday, but it also announced a pause in its late-stage coronavirus vaccine trial.
Eli Lilly shares made a handy gain on Wednesday after the company announced an update to its SARS-CoV-2 neutralizing antibody programs.